initi coverag life scienc diagnost
dont wan na product environ want
environ product
remain posit tool despit ralli recogn like late cycl
broadli posit life scienc tool dx complex given
favor cyclic bia strong secular growth driver continu margin
expans consolid might point elev valuat across
univers lack tax reform benefit still see favor core growth driver
like help sustain multipl market standpoint industri
appli sustain elev level pharma normal modestli msd
rate demand like acceler develop market china remain
key swing factor core growth recoveri well time geograph
see strength eu uk continu modest posit upsid bia
us japan china remain key swing factor global growth
overal close monitor macro trend china comp decidedli
challeng signal moder demand albeit like
manag vs dramat margin standpoint price continu
favor despit recent fear compani optim
cost structur see healthi increment broadli strong also allow
activ capit deploy roll ldd ep growth thu see rel
valuat gener appropri remain construct univers
thing watch china growth cadenc global pmi inflect
debat goe chinaso goe tool sustain secular tw
bio-product futur gener sequenc
industri growth forecast forese core growth rate sustain msd
pharma demand improv outlook academ govern main
swing factor remain china see growth deceler hsd
compress materi would note recent macro commentari
china merit watch see moder manag
valuat price target across complex impli market cap weight price-to-earnings
exclud termin growth rate dcf primari valuat
metric compar price-to-earnings rang average
pleas note forecast current ignor tax reform relat upsid
ep less relev tool complex dcf analysi adjust updat
cash tax rate thu view point valuat reflect reform pass
downsid risk potenti deceler china base demand given
govern desir fix structur problem maxim growth risk
biopharma demand may stall given slow biotech fund increas major
pipelin challeng fear price threat tax reform yield renew
push attack budget deficit leverag us lead declin nih fund
upsid risk improv underli econom trend develop market
lead notabl capital-expenditure resurg inflect demand upward budget
inflect posit invest percentag rise key part
world given breakthrough advanc technolog unleash massiv
clinic opportun result dx super-cycl boost industri growth broadli
compani initi outperform
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi coverag life scienc dx tool
dont wan na product environ want
environ product
last page report import disclosur regard stock report
tabl content
industri debat sustain secular tw bio-product
industri debat futur gener sequenc
 bull bear debat thesi
butcher
gang newyork
remain construct tool despit ralli recogn like late cycl trade overal
broadli posit life scienc tool dx complex given favor
cyclic bia strong secular growth driver continu margin expans consolid
might point elev valuat across univers lack tax reform
benefit still see favor core growth driver like help sustain multipl
market standpoint industri appli sustain elev level pharma
normal modestli msd rate demand like acceler develop market
geograph see strength eu uk continu modest posit upsid bia
us japan china remain key swing factor global growth overal
close monitor macro trend china comp decidedli challeng
signal moder demand albeit like manag vs dramat
margin standpoint price continu favor despit recent fear
compani optim cost structur see healthi increment broadli
strong also allow activ capit deploy roll ldd ep growth
thu see rel valuat gener appropri remain construct univers
thing watch china growth cadenc global pmi growth inflect
rel valuat point veli skew risk reward across complex
china growth acceler past year remain strong despit tough comp
heighten focu provid secular tw
macro support continu strength nt
china spend expect surpass us earli
china remain key global growth driver w/ broaden industri contribut demand pictur
although bullish long-term manag team take cautiou tone nt due tough comp
transit invest cycl basic research appli research expect continuenew plan call
mm peopl connect wastewat discharg directli store water today ad
new plan support cleaner china safer food suppli expans healthcar across countri baird
china certain student bodi left/right economycr dynam fast move marketchina pent-up
industri demand busi start see demand come back baird
expect moder hsd look due tough comp much benefit pent demand
solid across market biopharma strong new cfda reg indust food/env materi charact
expect china maintain hsd growth rate
see recoveri industri end market would disappoint didnt see pick bit
go forward anticip moder rapid growth last year comp
china remain secular tw although normal hsd surpris
debat sustain secular tw bio-product
strong bio-product demand drive pharma growth biolog becom greater portion portfolio
chemic nme approv
bla
biolog develop
major pipelin held emerg biopharma
robust fund keep demand elev
public biotech compani
debat futur gener sequenc
expans due low seq cost clinic oppti
day gold rush play clinic space
list certainli exhaust
thu nt oppti remain small advanc clinic
face sever hurdl reach broad adopt
technolog applic next year
outsid specialti translat institut
regulatory/inclus treatment guidelin slowli
includ acceler studi show benefit
current recommend
ethic like less issu appear
w/ learn incur diseas
cost data storag eclips cost sequenc
develop ont tech
mani liquid biopsi cdx collabor
broad adopt oncolog rare diseas
expect next year
shake crowd sequenc market
compani race bottom sequenc cost
use hai antimicrobi resist
expect next year
amazon acquir everi genom co realli
outsid current leverag level suggest like see continu tuck-in vs strateg deal
capac market cap
market still fragment outsid larg public
thu expect
capac appetit
luca brasi sleep fish godfath
tool growth like remain rang bound msd strong
posit macro point uptick proprietari macro model match construct management commentari
valuat trend higher due tw healthcar port storm
tool mult remain lofti given cyclic tailwind within complex unsettl polit uncertainti threat
risk point favor risk/reward profil strong macro continu consolid vs growth style shift
potenti deceler china base demand given govern desir fix structur problem maxim growth
risk biopharma demand may stall given slow biotech fund increas major pipelin challeng fear price
threat tax reform yield renew push attack budget deficit leverag us lead declin nih relat fund
improv underli econom trend develop market lead notabl capital-expenditure resurg inflect demand upward
 budget inflect posit invest percentag rise key part world given breakthrough
advanc technolog unleash massiv clinic opportun result dx super-cycl boost industri growth broadli
chart evercor isi factset
bull bear debat skew favor remain select
industri fire
best class ep growth
pharma cycl fume
valuat nose bleed level
consolid pace slow
transform middl inning superior ep growth w/ repatri upsid
forecast ep upsid improv realiti alreadi reflect valuat
strong novaseq new prod momo clinic oppti omx pull back
superior ep growth consist execut rel valuat limit upsid
ep inflect reflect absolut valuat await core confirm
correct post attract entri prior broad base growth inflect
best class tsr nonsens pull-back notabl buy opportun
predict ep trajectori boost repatri market effici win
know fredo broke heart
initi outperform pt
wan na play cyclic okay say hello littl gc
last page report import disclosur regard stock report
tabl content
debat recent slowdown biopharma growth tempor
debat like surpris upsid
debat right level peak margin
point differenti vs st
iv valuat risk elev price-to-earnings reflect beat
 conclus initi o/p cyclic bias growth
high-end analyt provid midst transform
acg effort help balanc product portfolio
divers analyt technolog provid strength
life scienc appli market well emerg
thesi superior ep growth given cyclic bia core
peer omx consist capit return buoy nt
tax reform repatri support elev valuat
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
tighten biopharma capital-expenditure budget
outsiz exposur china pharma
ceo mcmullen led transform effort
previous presid
jacob thaysen presid diagnost genom
join dako acquisit
suppli chain yr
debat recent slowdown biopharma growth tempor
agil saw greater biopharma deceler peer
mani concern durat current capital-expenditure cycl
howev reason weak appear tempor
new product provid momentum
tough comp face comp
manag anticip deceler
lumpi revenu due batch-bas orders/project
infin ii lc launch end
later inning yr lc upgrad cycl
ultivo triple-quad lc/m launch end
cycl infanc contribut next leg growth
infin wind
europ longer sale convers cycl couldnt convert
high-end mass spec order sale time
lc replac cycl small molecul deceler
expect given tail end infin ii cycl
earli inning like contribut overal
growth next yr
new product replac workhors instrument field
year
management guidanc growth appear attain given new product momentum
debat like surpris upsid
 o/p end market last
agil also o/p rest tool industri
major recoveri chemic side
feel stable/improv
 side troubl
year
increas capital-expenditure
role recoveri
start see
improv
refin side
 revenu subseg
 growth like major driver ep upsid
debat right level peak margin
manag done tremend job drive omx
plenti omx left despit close gap peer
gain like continu come dgg
major omx
came dgg
model summari point differenti vs street
swing factor pharma use repatri proce bia capit alloc
point differenti
core still
remain key peer
ep st w/
capit alloc
repatri
forecast like conserv core w/ repatri usag crucial
million except per share data fy end decemb scienc appli market organ genom organ cross organ measurementtot organ gp less total scienc appli market genom cross op less ep share inc net inc price-to-earnings prem disc januari
valuat undeni elev consist rel basi
agil longer inexpens superior growth trajectori support rel premium
risk point favor risk reward profil macro factor point posit revis vs capital-expenditure moder
potenti downward shift volatil oil price subdu demand relat analyt instrument
increas scrutini drug price place downward pressur budget limit capital-expenditure demand within complex
slowdown china relat demand given shift govern polici materi depress key geograph driver core growth
overinvest preoccup strategi divert manag attent away core dgg lead mix execut
manag use repatri process pay debt leav balanc sheet woefulli underutil limit return
slowdown core revenu unwilling flex cost structur yield margin compress evok imag agil pre mike
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
transform middl inning allow superior ep growth w/ upsid kicker repatri
unabashedli bullish share agil time buy
transform led ceo mcmullen argu rel price-to-earnings expans growth improv
multipl expans portion trade certainli play still see superior
growth profil given outsiz exposur cyclic end market averag omx potenti
enter see upsid estim continu strength potenti us
would also result better model omx core drive outsiz increment
omx also like see continu boost optim exist infrastructur well
effort drive continu improv across entir suppli chain
anoth key potenti medium-term driver ep upsid tax reform agil substanti
off-shore cash could brought back lower debt level also aggress buy share
furthermor see limit downsid risk slowdown pharma europ tough
comp like follow moder demand dynam within forecast
new product momentum pharma vertic also robust allow averag
share captur even case pronounc capital-expenditure slowdown unlik view
all-in see strong mid-to-high teen ep growth go forward abl
sustain premium in-lin histor level despit improv growth
given dynam see risk reward favor thu initi share o/p rate
thing watch global pmi oil price capital-expenditure commentari repatri
initi pt
far back rememb alway want
last page report import disclosur regard stock report
tabl content
debat market outlook nmr
debat much omx possibl
financi model recoveri like choppi
point differenti vs st
iv valuat risk hang fruit complet
 conclus initi stock price inflect
notabl overweight instrument
market leader high valu analyt technolog
focus molecular materi research well
industri appli analysi
thesi core growth improv new product
momentum strong second phase transform
challeng share alreadi reflect optim
rate valuat pt pt
ebitda vs average
price-to-earnings vs average
risk semi slowdown nano mix growth
consist helm notabl frank visionari
also presid dalton
previous cfo emd millipor
previous evp veeco
debat market outlook nmr
nmr market growth soft mix post stimulu
saw shift demand high field low field
offer high end high field mhz low
demand shift favor low field high field
direct contrast greater demand high field
includ larg ghz order
led tough comp
strong demand high field asia
partli due way fund work across
geographi europ bounc back us stabl
partli due mgmt focu expand end market
applic commerci organ away
tradit academ lab
expand scope tech drive futur growth
mix outlook low field help off-set high field hw
manag aim reduc cyclic expand
scope technolog open end market new
get away tradit academ lab
make tech applic pharma appli
industri end market need
focus commerci market instrument
need user-friendli softwar servic
lt nmr histor lsd busi trend
expect continu
high field face hw new cryo-em technolog
complementari technolog right
current fund demand cryo-em vs high field
structur biolog lab like nmr
new fund may put toward new cryo-em tech
dynam go sinc
acquir fei expect carri mt
demand expect shift back high-field nmr
cryo-em cycl later stage
meantim low field demand expand
applic expect mitig high field hw
forecast lsd growth nmr continu mix shift market expans aid soft
debat much omx possibl
manag done solid job omx sinc
due restructur program laid
management institut restructur program intend
right-siz busi drive profit
facil consolid factori
intern reorgan brought independ
busi group better oversight
mold cast product
right size portfolio cost structur
exit cam busi
focu oper excel
past year manag execut
restructur plan pick low hang fruit
basic oper structur place
step focu oper excel
institut lean initi facil
synchron across geographi still
geographi system
bring nwc in-lin peer
phase restructur nuanc
oper notable/dramat chang
still plenti omx runway left close gap w/ peer
omx like continu measur pace degre core growth influenc magnitud
calid nano cyclic add growth volatil
management aim transform portfolio lessen impact
focus key growth initi
push nmr front w/ ipcn key partner
new consum product biotyp asm launch
focu growth enterpris recur revenue
nt cyclic tw semi cycl still leg
recent help reduc cyclic exposur
management ramp activ last year follow
 moratorium heavi lift restructur
major asset increas exposur cyclic market
other bring capabl new growth area
model summari point differenti vs street
swing factor durat nano semi upsid biospin order trajectori bia capit alloc
point differenti
model core
improv remain
low end peer
omx remain strong
manag
target
ep st w/
capit alloc fx
impli premium
trend histor level
growth reacceler crucial ep upsid low hang fruit complet cost
million except per share data fy end decemb organ supercon organ organ gp less total supercon op less ep share inc net inc price-to-earnings prem disc januari
valuat appear fair street profit forecast
overal valuat metric stabl albeit rel compress given down-tick core outlook
risk point balanc risk reward profil upsid new product cyclic need valid valuat
downtick semi relat indic could result notabl pullback nano demand outpac segment
wallet share loss cryo-em high-field nmr could make biospin growth challeng lessen omx potenti
uptick activ favor recent albeit histori show risk valu centric buyer think calid
new product momentum could prove materi forecast estim allow achiev state omx goal
activ return capit via repurchas increas util improv balanc sheet could bia ep upward
upsw budget global could allow strong demand across nmr ms portfolio bias core growth msd
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi pt upsid
forecast depict ep upsid valuat alreadi fulli adjust improv realiti
miss materi run share came heel challeng
core growth return posit territori om continu upward march
notabl inflect growth come key cyclic vertic within calid
nano merit watch enter semi industri appear posit bias
furthermor margin standpoint shift sole benefit tax plan
nmr price true underli cost improv much challeng
addit management also supplement cyclic uptick better om impress new
product momentum renew focu broaden market away tradit
coupl activ capit deploy result low teen ep growth
compar modest growth seen due challeng tax comp
despit dynam core growth like remain low end peer given market factor
nmr high end weak well continu ownership highli volatil best divis
turn valuat contend share alreadi price st forecast upsid
core north requir order push share well current level
see less likelihood portfolio diversif effort typic take multipl
year order influenc core rate notabl fashion
given dynam see risk reward balanc thu initi share rate
thing watch nano calid core commentari high-end nmr om trajectori
initi outperform pt
alway winner start gate
last page report import disclosur regard stock report
tabl content
debat see bottom dental recoveri viabl
debat lt outlook pll chang mix
point differenti vs st
iv valuat risk dental challeng abat
 conclus initi o/p growth mean revers
portfolio undergon complet transform
global famili greater oper compani
focus life scienc dental diagnost
thesi growth recov post challeng pll
dental recent synergi build
b/ prime capit deploy
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk continu growth challeng dental unit
rich valuat stymi capit alloc cadenc
deep bench w/ db secret sauc across divis
debat recent reshap core margin profil lt
strateg spin transform industri scienc tech centric conglomer
spun bn industri revenu
 shift product mix toward consum
debat recent reshap core margin profil lt
db playbook strong histori improv core growth drive bp omx annual
current rev compani own yr
revenu
revenu
core/omx like
acceler given
average age portfolio today yr
debat see bottom dental recoveri viabl
dental u/p dental market rest
dig deeper segment tale citi
challeng face tradit consum busi
overshadow improv made nobel
db drove solid improv busi nobel
manag treat entir dental like new
acquisit appli db aggress
brand/opco consolid took opco
increas
manag feel begin see fruit db
platform grow lsd/msd
indirect imag equip etc kavo lsd
china post dd growth consist mt
particularli us bit eu dental
us distributor de-stock issu continu period rear
head last seen earli
channel disrupt due break exclus w/
siro/xray open cad/cam market
bottom
recov lt
debat lt outlook pll chang mix
hw macro tough comp hurrican
industri tough comp larg mid east project
industri middl east comp overal macro still
comp pll life scienc deceler
life dd singl use signific hw
hurrican week shut puerto rico de-
stock bioprocess custom
investor wari bioprocess slowdown
bioprocess slow due sever key account de-
base pipelin expect increas demand
stock better manag inventori
base peer commentari investor concern someth
structur could play given biopharma strong growth
last coupl year
larger biopharma custom de-stock like impact
compound tough dd comp past sever
bioproduct lumpi businesssaw custom
manag inventori
bioprocess msd see larg key account de-
stock clear idea stop merck kgaa
biolog biosimilar vaccin enter market
single-us technolog continu growth driver dd
view growth challeng tempor see acceler beyond
model summari point differenti vs street
swing factor dental trajectori pace pll recoveri cadenc capit alloc
point differenti
revenu st
year core
synergi ramp
ep st w/
capit alloc
leverag remain
manag level
like prove activ mid-siz drive ep upsid
million except per share data fy end decemb appli organ organ organ organ organ gp less total appli op less ep share inc net inc price-to-earnings prem disc januari
rel valu appeal basi improv
near-term valuat elev ebitda metric appear compel rel price-to-earnings
risk point favor risk reward profil delay dental growth re-norm vs pll acceler
potenti continu pressur across dental channel given chang distributor relationship overal mute volum
slowdown china relat demand given shift govern polici materi depress key geograph driver core growth
biosimilar uncertainti yield continu inventori work pall result anoth year average revenu momentum
elev valuat multipl rise rate depress activ result modest ep upsid capit alloc
dx revenu stagnat tough flu comp limit volum growth challeng strong cphd perform limit bec
municip budget face challeng given increas global polici uncertainti pressur water demand constrain core rate
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
bullish share time mark expect turn point
core growth recent acquisit anniversari portfolio transform took hold
underli dynam thesi take hold perform somewhat mask
challeng dental busi surpris deceler pall key segment
enter contend sever headwind resolv
expect improv perform even across dental segment balanc
pall see recoveri bioprocess demand inventori de-stock appear complet
industri benefit macro factor well pass tough comp
respect dental see slow steadi recoveri channel issu resolv
underli weak basic consum start comp remain bullish lt
turn key segment see stabl improv growth cite strong macro
outlook core momentum includ cphd core upwardli bia dx
furthermor expectedli quiet anticip pace pick-up
balanc sheet return flexibl level albeit caution public valuat elev
valuat front multipl certainli inexpens see sustain
tradit rel premium believ may even re-expand see core acceler
given dynam see risk reward favor thu initi share o/p rate
thing watch global pmi dental trend share commentari activ
initi outperform pt
last page report import disclosur regard stock report
tabl content
compani overview world leader genet analysi
debat novaseq adopt curv
debat long array growth remain elev
debat next big opportun clinic genom
point differenti vs st
iv valuat risk
 conclus initi o/p new product momentum
san diego ca world leader genet analysi
domin provid microarray tool
sequenc technolog life scienc clinic
market w/ notabl presenc array
thesi early-to-mid cycl uptak novaseq
inflect clinic demand continu new product
momentum improv omx cadenc must
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk uptak clinic take longer
sequenc consum key product segment
new manag built histori innov
join symantec
join cardin health
mostafa ronaghi svp
co-found acceler
join variou role genentech
visionari overal genom gangster
debat novaseq adopt curv
surpass initi expect placement
surprisingli upsid come commercial/clin
still earli w/ cust like speed adopt
believ support elev multipl
yet dent initi address high
earli demand novaseq
order come custom new
sequenc new high throughput sequenc
hiseq custom upgrad
major custom wait chip
earli launch acceler replac
thu drive next leg adopt
though earli day nova launch initi success like sustain elev multipl
debat long array growth remain elev
declar dead array roar back life
servic drive much improv growth
array total rev
servic array rev
array servic demand driven dtc opportun
enjoy last dtc convert
ilmn array backlog grown highest level sinc
array appear back near term servic
growth driven larg rabid demand dtc genom
howev difficult tell dtc genom
convert wide acknowledg happen
cost continu drop
tend believ array rel safe
transit next year two
lt imagin array nich product use
confirm result front prep studi etc
larg commodit growth
reflect dynam
lazaru genom provid nice nt boost core like long-liv
debat next big opportun clinic genom
open clinic market key expand tam
liquid biopsi test materi unlock clinic
liquid biopsi technolog wide consid
key unlocking/expand clinic genom market
cancer diagnos use liquid biopsi
hand test develop approv
holi grail pardon pun cancer test
spun grail develop test major
challeng exist expect updat trial progress
aim develop annual screen test
given peopl risk develop cancer
year key valid thesi
nascent market liq biopsi oppti massiv
new applic tech present notabl expans
liquid biopsi market mm today
major
address
liquid biopsi like compel mt oppti
singl cell provid understand differenti
requir lot sequenc small project
 lower sequenc cost expand potenti
cdx i/o i/o drug develop
receiv approv china nextseq nipt
launch veriseq nipt europ
consum genom increas number compani
w/ high-risk screen repres biggest oppti
model summari point differenti vs street
swing factor pace instrument growth degre novaseq util next leg growth
point differenti
pace adopt
begin normal
hit full run-rat
ep notabl st
growth cash unlock
multipl normal
key product
revenu momentum continu given improv omx drive ep beat
million except per share data fy end decemb sequenc organ gp less op less ep share inc net inc price-to-earnings prem disc januari
valuat elev correspond w/ mid-cycl growth path
pt in-lin w/ long term averag price-to-earnings correspond p/e/g consist w/ growth asset
risk point favor risk reward profil delay clinic uptak vs sheer opportun
potenti disrupt us fund given challeng feder budget us could delay uptak new capit purchas
difficulti relat scale comput power storag rate data gener could limit pace clinic adopt
time-frame translat scientif discoveri tangibl clinic applic take longer fear given unforeseen complex
emerg technolog prove scalabl contempl slowdown yield materi shift long term share
array return challeng growth given increas competit well draw back relat tool consum
style shift growth valu compress multipl broadli lead notabl step-down absolut valuat metric
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris tax valu grail total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
strong novaseq growth new product momentum clinic opportun improv omx pull back
upgrad share earli last year like boldest call year cover
stock hard get drawn compel new product cycl inde
turn clock expect broaden adopt launch
chip crucial get high volum user onto new system support box growth
furthermor see plethora new opportun clinic front oncolog clearli
star promis liquid biopsi ever present term long term expans
also look array demand sustain slightli elev level consum market fuel
strong servic growth base nih budget increas help tradit research
anoth potenti upsid surpris could come form notabl new product introduct
focu next week littl chatter new box possibl applic
may point valuat limit would note increment margin
gain momentum upsid bia could see ep estim move higher
speak valuat believ continu strong instrument momentum sustain
elev multipl broadli allow superior growth profil remain
roll remain one uniqu growth stori across entir market
leverag futur cancer person medicin via domin presenc
given dynam see risk reward favor thu initi share o/p rate
thing watch pace novaseq placement util new product intro
initi pt
look ross rememb
last page report import disclosur regard stock report
